Clinical Trials Browser

MLN 8237 × Lymphoid × Clear all

NCT01695941 2026-03-18

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase 2 Completed

118 enrolled 24 charts

CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02259010 2019-09-20

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Phase 1 Completed

24 enrolled 26 charts

Lymphoma

NCT01898078 2019-06-21

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

Phase 1 Completed

26 enrolled 20 charts

Lymphoma

NCT01844583 2019-03-25

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Phase 1 Completed

55 enrolled 29 charts

Lymphoma

NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Phase 1 Completed

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01714947 2018-10-31

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

Phase 1 Completed

3 enrolled 32 charts

Lymphoma

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

NCT01812005 2018-06-06

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

14 enrolled 11 charts

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00807495 2018-03-27

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

48 enrolled 18 charts

Burkitt Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01397825 2018-03-27

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Phase 1/2 Completed

45 enrolled 24 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02700022 2017-11-20

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Phase 1 Terminated

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01466881 2016-03-10

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell